81 results about "A Antibody" patented technology

The present invention provides novel monoclonal antibodies directed to P1GF and fragments and derivatives thereof, more particularly to humanized antibodies and fragments thereof for use in the treatment and / or prevention of pathological angiogenesis.

The invention belongs to the field of antibody detecting biochip which is based on piezoelectric effect, especially relates to a antibody detecting biochip using piezoelectric film acoustic wave device; including resonator FBAR which is equipped with upper electrode, bottom electrode and bragg reflection layer whole reflection film, the character of it resides in that: the piezoelectric film is equipped between the upper electrode and bottom electrode on resonator, the bragg reflection layer whole reflection film includes loudness acoustic impedance and undertone impedance, the loudness is composed of metal Mo, the undertone is composed of metal Al; the FRAB working frequency is 0.1-10GHz, the range of Q value is 100-2000; metal layer is planted on upper electrode, protein and antibody tissue are attached on the metal layer; the invention can measure resonance frequency migration parameters of antibody tissue and antigen, then specific antigen content is obtained; the sensor can be integrated on the chip, at the same time can sense micro antibody material, and creates favorable conditions for measuring trace amount of biological materials in body fluid.

The invention discloses a kit for detecting the content of a serum amyloid protein A. The kit comprises a reagent R1, a reagent R2 and a serum amyloid protein A calibrator, wherein the reagent R1 comprises a first buffer solution, a first electrolyte, a surfactant, a first stabilizer, a high-molecular accelerant and a first preservative; the reagent R2 comprises a second buffer solution, anti-human serum amyloid protein A antibody coated latex particles, a second electrolyte, a second stabilizer and a second preservative; the serum amyloid protein A calibrator comprises a third buffer solution, a third stabilizer, a third preservative, an antioxidant and an anti-human serum amyloid protein A antigen. The invention further discloses an application of the kit for detecting the content of the serum amyloid protein A to the detection of the content of the serum amyloid protein A and a method for detecting the content of the serum amyloid protein A by adopting the kit for detecting the content of the serum amyloid protein A. By adopting the kit and the method disclosed by the invention, the content of the serum amyloid protein A can be detected easily and rapidly.

Disclosed are humanized antibodies that bind specifically to TNF superfamily member 15 (TNFSF 15), also known as TLlA. Methods of making and using the anti-TLl A antibodies are also described. The humanized antibodies may be antagonists and may used to treat or diagnose conditions associated with TLlA function.

The present invention discloses compositions which induce cross-activation of immune mediated and direct death signaling in targeted cells by exploiting the properties of a antibody / peptide-nucleic acid conjugate. The conjugate is able to simultaneously activate multiple death signaling mechanisms that are specifically targeted to neoplastic cells, including tumor cells. Methods of using the conjugate of the present invention as an immunotherapeutic modality for the treatment or prevention of neoplastic diseases or other disorders is also disclosed. Further, methods are disclosed for identifying such conjugates by assaying test agents for various cytotoxic responses, including the induction of hyperfusion between neoplastic cells in vitro.

Provided herein are anti-VEGF-A antibodies and antibody conjugates thereof. Some embodiments of the antibodies can be conjugated to a moiety, such as a HEMA-PC polymer. Some embodiments of the antibody conjugates can retain or enhance antibody activity. The antibody and conjugate thereof can be particularly useful for treating diabetic retinopathy. Further provided are methods for conjugation of a polymer to a protein such as an antibody, such as IgG1.

The present invention provides: an antibody or a antibody fragment thereof, which can bind to A33, which specifically attacks A33-expressing tumor cells with the use of ADCC and CDC based on the immune system, and for which no HAHA is produced; and a preventive or therapeutic agent for various malignant tumors including solid tumors that are currently treated with difficulty, which contains the antibody or an antibody fragment thereof. Specifically, the antibody or a functional fragment thereof is capable of binding to A33 and is produced by a hybridoma M10 (accession No. FERM BP-10107), M96 (accession No. FERM BP-10108), M165 (accession No. FERM BP-10106), N26 (accession No. FERM BP-10109), Q47 (accession No. FERM BP-10104), Q54 (accession No. FERM BP-10105), or R5 (accession No. FERM BP-10107). The preventive or therapeutic agent for tumors contains the antibody or a functional fragment thereof.

Anti-NTB-A antibodies and antigen-binding fragments thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding fragments are described. Also described are methods of using such antibodies and antigen-binding regions to bind NTB-A and treat diseases, such as hematologic malignancies, which are characterized by expression of NTB-A.

The invention discloses an indirect ELISA method and kit for detecting serum 3-type duck hepatitis virus a antibody and belongs to the technical field of serum antibody detection. The indirect ELISA method includes that serum 3-type duck hepatitis virus VP1 protein is utilized as an envelope antigen with the peridium quantity as 0.1-1mug per hole, HRP-mice anti-duck IgY is utilized as the HRP with the use concentration as 0.2-2mug / mL, and the coloration time is 10 minutes. The kit comprises a VP1 protein antigen envelope board, the HRP-mice anti-duck IgY, sample diluent, a scrubbing solution, TMB solutions A and B and a stop solution. The method and the kit can be used for detecting the serum 3-type duck hepatitis virus a antibody in duck serum and duck egg yolk, and the serum does not have cross reaction with positive serum of other viruses. Compared with a traditional neutral reaction detection method, the method has the advantage of being convenient and accurate.

The present invention provides: an antibody or a antibody fragment thereof, which can bind to A33, which specifically attacks A33-expressing tumor cells with the use of ADCC and CDC based on the immune system, and for which no HAHA is produced; and a preventive or therapeutic agent for various malignant tumors including solid tumors that are currently treated with difficulty, which contains the antibody or an antibody fragment thereof. Specifically, the antibody or a functional fragment thereof is capable of binding to A33 and is produced by a hybridoma M10 (accession No. FERM BP-10107), M96 (accession No. FERM BP-10108), M165 (accession No. FERM BP-10106), N26 (accession No. FERM BP-10109), Q47 (accession No. FERM BP-10104), Q54 (accession No. FERM BP-10105), or R5 (accession No. FERM BP-10107). The preventive or therapeutic agent for tumors contains the antibody or a functional fragment thereof.

The present invention provides antigen binding proteins that specifically bind to Wilms' tumor protein (WT1), including humanized, chimeric and fully human antibodies against WT1, antibody fragments, chimeric antigen receptors (CARs), fusion proteins, and conjugates thereof. The antigen binding proteins and antibodies bind to HLA-A0201-restricted WT1 peptide. Such antibodies, fragments, fusion proteins and conjugates thereof are useful for the treatment of WT1 associated cancers, including for example, breast cancer, ovarian cancer, prostate cancer, chronic myelocytic leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), acute myeloid / myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). In more particular embodiments, the anti-WT1 / A antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and / or expression levels.

The invention relates to a antibody for identifying a B7-H3 protein, a double-specific antibody for identifying the B7-H3 protein and CD3, and a manufacturing method and application thereof.

Provided herein is a means which is effective for botulism diseases and the prevention of the botulism diseases. Specifically provided is a plurality of human anti-botulinum toxin type-A antibodies having different epitopes from one another. Also specifically provided is a composition for neutralizing botulinum toxin type-A, which comprises a combination of two or more of the antibodies and which has a high neutralizing activity.

The invention discloses an indirect ELISA kit for detecting Haemophilus paragallinarum type A antibody, a detection method and an application thereof, and relates to the technical field of biological detection. The ELISA kit of the present invention includes: coated microplate, washing solution, serum diluent, substrate chromogenic solution, rabbit anti-chicken enzyme-labeled secondary antibody, stop solution, type A Hpg standard positive serum and type A Hpg standard negative serum Serum; wherein, the coated microtiter plate uses the recombinant hemagglutinin protein of Haemophilus paragallinarum type A as the coated antigen. The ELISA kit of the present invention is used to detect the antibody of Haemophilus paragallinarum type A, and has the advantages of high efficiency, good sensitivity, specificity and repeatability, and the kit is easy to operate, fast and low in cost, and is suitable for clinical applications and promote.

In order to provide a antibody against hIL-33 with clinical application prospect, the invention provides a high-affinity mouse anti-human IL-33 antibody by adopting a panning technology of immunizingmouse B cells, based on the action mechanism of IL-33 in inflammation and tumors in the prior art, the function of IL-33 in regulating cytokine secretion, and cytokines involved in inflammation and tumors. After recombinant expression of mouse-derived antibodies, preliminary screening of biological activity, humanization transformation, affinity maturation and biological activity rescreening, a humanized monoclonal antibody against hIL-33 is obtained, and the monoclonal antibody has the characteristics of high stability, high affinity, good biological activity, broad clinical application prospects, etc.

The invention discloses an AB / CDE blood type grouping reagent card. The reagent card is provided with eight microcolumn gel tubes, namely a gel tube containing an immune globulin (IgM) monoclonal anti-A antibody, a gel tube containing an IgM monoclonal anti-B antibody, a gel tube containing an IgM monoclonal anti-D antibody, a gel tube containing an IgM monoclonal anti-C antibody, a gel tube containing an IgM monoclonal anti-E antibody, a gel tube which is used for negative control and contains a gel buffer solution and two gel tubes which are used for reverse typing and contain gel buffer solutions. The invention provides standard for the ABO-CDE blood type grouping; and the ABO-CDE blood type grouping reagent card which conforms to standard can be used in all hospitals and blood transfusion services to accurately group ABO-CDE blood types, so conditions are created for guaranteeing transfusion safety.

The invention relates to a serum amyloid protein A (SAA) measuring kit, and a measuring method thereof, and belongs to the technical field of medicine biological detection. The kit comprises a reagent (1), a reagent (2), a calibration material, and a quality control material. The reagent (1) comprises Tris-HCl, sodium azide, and PEG-6000. The reagent (2) comprises Tris-HCl, emulsion particles with an embedded anti-human serum amyloid protein A antibody, sodium azide, octyl phenol polyoxyethylene, and methyl paraben. The calibration material comprises a serum amyloid protein A antigen, and sodium azide. The quality control material comprises a serum amyloid protein A antigen, and sodium azide. The provided serum amyloid protein A (SAA) measuring kit and measuring method thereof have the advantages that compared with the latex immunological turbidimetry technology, the analysis sensitivity is high, the results are accurate, the operation is simple, and the cost is proper, and thus the method is convenient for popularization.

The invention relates to a serum amyloid protein A (SAA) measuring kit, and a measuring method thereof, and belongs to the technical field of medicine biological detection. The kit comprises a reagent (1), a reagent (2), a calibration material, and a quality control material. The reagent (1) comprises Tris-HCl, sodium azide, and PEG-6000. The reagent (2) comprises Tris-HCl, emulsion particles with an embedded anti-human serum amyloid protein A antibody, sodium azide, octyl phenol polyoxyethylene, and methyl paraben. The calibration material comprises a serum amyloid protein A antigen, and sodium azide. The quality control material comprises a serum amyloid protein A antigen, and sodium azide. The provided serum amyloid protein A (SAA) measuring kit and measuring method thereof have the advantages that compared with the latex immunological turbidimetry technology, the analysis sensitivity is high, the results are accurate, the operation is simple, and the cost is proper, and thus the method is convenient for popularization.

In a first aspect, the present invention relates to a recombinant polypeptide containing a domain comprising at least two antibody units whereby the first antibody unit is an anti-CD30 single chain antibody unit while the second antibody unit is a antibody unit being specific for an antigen present on the surface of a predetermined target cell. In particular, the present invention relates to a recombinant polypeptide containing at least the following domains starting from the N-terminus to the C-terminus: a first domain containing an anti-CD30 single chain antibody unit, in particular, HRS3 scFv of SEQ ID No. 2 or homologs thereof having at least 70% identity with SEQ ID No. 2 binding specifically to CD30, and an antibody unit said antibody unit being specific for an antigen present on the surface of a predetermined target cell, in particular, being specific for a tumor-associated antigen; optionally a spacer domain; a trans-membrane domain; and a cytoplasmatic signalling domain. In a further aspect, the present invention relates to a nucleic acid molecule encoding the polypeptide according to the present invention, as well as vectors and cells containing the same. Moreover, lymphocytes are provided, in particular T-cells like CD8+ or a CD4+ T-cell expressing on its surface chimeric antigen receptors containing an anti-CD30 single chain antibody unit and an antibody unit whereby said antibody unit being specific for an antigen present on the surface of a predetermined target cell. Immune cells modified with the polypeptide show improved functions, in particular in the treatment of cancer, in particular CD30− cancer. That is, the cells are for use in adapted cell therapy for treating cancer in a subject in need thereof.

The invention discloses application of an scFv antibody in a preparation used for treatment or prevention of the infectious bursal disease of chicken. The scFv-GD antibody provided by the invention comprises a heavy-chain variable region, a light-chain variable region and a joining region between the heavy-chain variable region and the light-chain variable region. The heavy-chain variable region is (a) or (b), wherein (a) is protein composed of the first to the 128th amino acid residues in a sequence 1, and (b) is protein derived from (a) through substitution and / or deletion and / or addition of amino acid residues and having same activity. The light-chain variable region is (c) or (d), wherein (c) is protein composed of the 144th to the 249th amino acid residues in the sequence 1, and (d) is protein derived from (c) through substitution and / or deletion and / or addition of amino acid residues and having same activity. The scFv-GD antibody is obtained through screening via antigen-antibody co-expression bacterium display techniques; the neutralization activity of the scFv-GD antibody is more than 10 times of the neutralization activity of a patented scFv-A antibody; and the scFv-GD antibody has the advantages of good specificity and better treatment effect.

The invention provides a method for increasing the yield of m<6>A antibody-enriched methylation mRNA. The method is characterized in that a prepared compound of m<6>A and methylation mRNA is eluted by eluent to obtain methylation modified mRNA, and the methylation modified mRNA is used for target gene methylation degree qRT-PCR analysis or high-throughput sequencing to analyze the methylation features of genes; the eluent comprises 0-0.2M of NaCl, 1-20mM of Tris with pH being 8.0, 0.5-5mM of EDTA, 0.01-0.5 of SDS and 1-300 microgram / L of proteinase k. The method has the advantages that the method is different from other methods, the method uses the protease k to elute the compound of the m<6>A and the mRNA, the methylation mRNA high in abundance is obtained, test cost is lowered greatly, test time is shortened, and an economical and effective test method is provided for the researches of m<6>A methylation modification.

The invention relates to a latex immunoturbidimetry detection kit for quantitatively determining cat serum amyloid protein A. The latex immunoturbidimetry detection kit comprises reagent beads formedby freeze-drying polystyrene latex particles sensitized by a cat serum amyloid protein A antibody, a reagent disc for detection, water cup water for diluting a sample, a cat serum amyloid protein A calibration product and a quality control product. The product can accurately and quantitatively detect the content of the cat serum amyloid protein A, can monitor the early inflammation of infectious diseases according to the content of the cat serum amyloid protein A, is beneficial to diagnosing inflammation, evaluating the activity of the cat serum amyloid protein A and monitoring the activity and treatment of the cat serum amyloid protein A, and has very high clinical value. The kit has the advantages of high specificity, high sensitivity, high precision, high accuracy, simplicity, convenience, quickness and the like.

The invention discloses a fusion protein of antibody Hepatitis B vaccine belonging to the bio-engineering field. It has two functional domains which composed of preS2 of Hepatitis B surface antigen in N-terminal and S protein, and IgG1 Fc in rats. The invention also discloses the vector containing the gene coding the said fusion protein. The invention also discloses a antibody Hepatitis B vaccine. The constructed antibody Hepatitis B vaccine may induce a strong humoral-mediated immune response and a cell-mediated immune response which has a better effect than the traditional vaccine.

The invention discloses a cyclosporine A immunological detection reagent as well as preparation and detection methods thereof. The cyclosporine A immunological detection reagent comprises cyclosporineA and an indication reagent for detecting a cyclosporine A antibody-enzyme labeled cyclosporine A compound, wherein enzyme labeled cyclosporine A is prepared by coupling cyclosporine A and glucose dehydrogenase. The cyclosporine A immunological detection reagent disclosed by the invention can be used for accurately and rapidly determining the content of cyclosporine A in samples of human blood and the like. Compared with existing detection reagents in the market, the detection reagent disclosed by the invention has the advantages of convenience and rapidness, high sensitivity, strong specificity, accurate quantification and the like, and clinical popularization and application are facilitated.

The invention discloses an enzyme linked immuno kit for detecting residual phenylethanolamine A and an application method thereof and belongs to the technical field of enzyme-linked immunosorbent assay methods. The enzyme linked immuno kit comprises an elisa plate coated by a benzene ethanolamine A antigen, phenylethanolamine A standard substance working solution, phenylethanolamine A antibody working solution, phenylethanolamine A IgG-HRP working solution, substrate solution, stop solution, concentrated washing solution and concentrated sample diluent. The enzyme linked immuno kit adopts an indirect competition enzyme-linked immunosorbent assay (ELISA) method. Residual phenylethanolamine A on the standard substance or the sample to be detected and an antigen pre-coated on the elisa plate contend for the phenylethanolamine A antibodies together. The application method can be used for directly detecting the phenylethanolamine A in animal derived food, urine samples, animal tissues and serum samples. The enzyme linked immuno kit has the advantages of being convenient, fast, sensitive and the like, and is suitable for detection of large-volume samples. In addition, the sensitivity of the enzyme linked immuno kit is 0.1ng / mL.